Diaceutics PLC (AIM:DXRX)
148.00
+2.00 (1.37%)
Jun 19, 2026, 8:27 AM GMT
Diaceutics Revenue
In the year 2025, Diaceutics had annual revenue of 38.44M GBP with 19.53% growth. Diaceutics had revenue of 23.87M in the half year ending December 31, 2025, with 73.31% growth.
Revenue
38.44M
Revenue Growth
+19.53%
P/S Ratio
3.22
Revenue / Employee
187.50K
Employees
205
Market Cap
123.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 38.44M | 6.28M | 19.53% |
| Dec 31, 2024 | 32.16M | 8.46M | 35.69% |
| Dec 31, 2023 | 23.70M | 4.20M | 21.51% |
| Dec 31, 2022 | 19.50M | 5.56M | 39.88% |
| Dec 31, 2021 | 13.94M | 1.25M | 9.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 45.77B |
| GSK plc | 32.78B |
| Haleon | 11.03B |
| Smith & Nephew | 4.58B |
| INSPECS Group | 191.70M |
| EKF Diagnostics Holdings | 51.56M |
| Tristel | 49.54M |
| Venture Life Group | 35.17M |
Diaceutics News
- 23 days ago - Diaceutics Earnings Call Transcript: H2 2025 - Transcripts
- 23 days ago - Diaceutics Annual report: H2 2025 - Filings
- 23 days ago - Diaceutics Annual report: H2 2025 - Filings
- 23 days ago - Diaceutics Slides: H2 2025 - Filings
- 24 days ago - Diaceutics Slides: Corporate presentation - Filings
- 24 days ago - Diaceutics PLC (LSE:DXRX) Q4 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
- 5 months ago - Diaceutics Earnings release: Q4 2025 - Filings
- 9 months ago - Diaceutics Quarterly report: H1 2025 - Filings